logo
Share SHARE
FONT-SIZE Plus   Neg

Valeant Pharmaceuticals Agrees To Buy Ophthalmic Biotechnology Company EyeTech

Specialty pharmaceutical company Valeant Pharmaceutical International Inc (VRX,VRX.TO) Monday announced that it has agreed to acquire Eyetech Inc., a privately-owned ophthalmic biotechnology company dedicated to the treatment of sight-threatening diseases of the retina, for an upfront payment and potential future milestones that total significantly less than two times sales.

Valeant stated that the transaction, which is subject to customary closing conditions, is expected to close this week. The transaction is expected to be immediately accretive.

Eyetech currently markets Macugen in the United States, the first anti-VEGF inhibitor approved for the treatment of wet age-related macular degeneration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Yelp Inc. (YELP) on Monday posted a loss for the fourth quarter compared to a profit last year, as higher revenues were offset by increase in operating costs. Yelp said its Chief Financial Officer Rob Krolik was leaving the company. Yelp reported fourth-quarter loss of $22.2 million or $0.29 per share,... Twenty-First Century Fox Inc., (FOXA, FOX) on Monday reported a second-quarter profit that dropped from last year, hurt largely by lower revenues as strong cable and television advertising revenues were offset by lower filmed entertainment division. Earnings for the quarter trumped Wall Street estimates... Toy maker Hasbro Inc. (HAS) reported a profit for the fourth-quarter 2015 that grew about 3.5% from last year. Quarterly net revenues increased 13% from the prior year. Both earnings per share and revenue for the quarter beat analysts' expectations.
comments powered by Disqus
Follow RTT